{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:13:14Z","timestamp":1788228794703,"version":"build-2803163510"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.fertnstert.2025.05.160","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T02:23:35Z","timestamp":1748053415000},"page":"577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining glucagon-like peptide-1 receptor agonist therapy in polycystic ovary syndrome: addressing phenotypic, racial, and pharmacologic heterogeneity"],"prefix":"10.1016","volume":"124","author":[{"given":"Shengyue","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2025.05.160_bib1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.fertnstert.2025.04.009","article-title":"Effect of glucagon-like peptide 1 agonist medications on weight loss in patients with and without polycystic ovary syndrome","volume":"124","author":"Gleason","year":"2025","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2025.05.160_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2024.100159","article-title":"When one size does not fit all: reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments","volume":"14","author":"Unfer","year":"2024","journal-title":"Endocr Metab Sci"},{"key":"10.1016\/j.fertnstert.2025.05.160_bib3","article-title":"Ethnic\/racial and geographic disparities on major cardiovascular events in glucagon like peptide-1 receptor agonists trials: a meta-analysis","volume":"48","author":"Lavalle","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.fertnstert.2025.05.160_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108823","article-title":"Race\/ethnicity and challenges for optimal insulin therapy","volume":"175","author":"do Vale Moreira","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.fertnstert.2025.05.160_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028225004480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028225004480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:23Z","timestamp":1788225383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028225004480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0015028225004480"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.05.160","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining glucagon-like peptide-1 receptor agonist therapy in polycystic ovary syndrome: addressing phenotypic, racial, and pharmacologic heterogeneity","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.05.160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.04.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 American Society for Reproductive Medicine, Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}